Search Results - "Kawabata, Rumi"
-
1
Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
Published in Cancer science (01-06-2020)“…HER2‐targeting antibodies (trastuzumab, pertuzumab) and a HER2‐directed antibody‐drug conjugate (trastuzumab emtansine: T‐DM1) are used for the treatment of…”
Get full text
Journal Article -
2
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways
Published in Cancer science (01-12-2019)“…The ubiquitin proteasome pathway is essential for the proliferation and survival of multiple myeloma (MM) cells. TAS4464, a novel highly potent inhibitor of…”
Get full text
Journal Article -
3
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells
Published in PloS one (16-04-2015)“…Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in debate. In addition to clinical studies, a priori…”
Get full text
Journal Article -
4
Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: Results of a multi-center randomized phase II study
Published in International journal of oncology (01-09-2013)“…We conducted this study to determine whether substitution with anti-androgen (SOA) and tegafur-uracil (a pro-drug of 5-FU) combination therapy is more…”
Get full text
Journal Article -
5
Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728
Published in Molecular cancer therapeutics (01-12-2019)“…Abstract Background: HER2-targeting antibodies (trastuzumab, pertuzumab) and an antibody-drug conjugate (trastuzumab emtansine: T-DM1) are available for the…”
Get full text
Journal Article -
6
DLST as a method for detecting TS-1-induced allergy
Published in Gan to kagaku ryoho (01-03-2006)“…Drug-induced allergic adverse events including rash, interstitial pneumonia and hepatic injury are often observed in a few patients treated with anticancer…”
Get more information
Journal Article -
7
Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Published in Molecular cancer therapeutics (01-01-2018)“…Abstract Background: HER2 is a well-established therapeutic target in breast and gastric cancer. Although HER2-targeting therapies are available for…”
Get full text
Journal Article -
8
Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines
Published in International journal of oncology (01-06-2011)“…In this study, we investigated the synergistic mechanism of anti-androgen and 5-fluorouracil (5-FU) combination therapy against castration-resistant prostate…”
Get full text
Journal Article -
9
Abstract 2757: TAS-106, a newly synthesized RNA polymerase inhibitor, combined with cisplatin exhibits potent synergistic growth-inhibitory effect via Vaults dysfunction
Published in Cancer research (Chicago, Ill.) (15-04-2012)“…Abstract TAS-106, 3′-C-ethynylcytidine, is a novel nucleoside analog that inhibits RNA polymerases I, II and III, and has been reported to exert potent…”
Get full text
Journal Article -
10
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells
Published in International journal of oncology (01-03-2011)“…We investigated the antitumor effects of combination therapy with anti-androgens and 5-fluorouracil (5-FU), and examined the underlying mechanism of the…”
Get full text
Journal Article -
11
Dynamic Modulation of Thymidylate Synthase Gene Expression and Fluorouracil Sensitivity in Human Colorectal Cancer Cells: e0123076
Published in PloS one (01-04-2015)“…Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in debate. In addition to clinical studies, a priori…”
Get full text
Journal Article